The FDA has eliminated Risk Evaluation and Mitigation Strategies (REMS) for six CAR T-cell therapies targeting multiple myeloma and certain leukemias and lymphomas. This move reflects confidence in established management guidelines and extensive clinical experience addressing cytokine release syndrome and neurotoxicity risks. Industry leaders view this regulatory change as a step toward broader adoption of CAR T therapies in community settings while reducing provider burden and expediting patient access. The decision underscores evolving regulatory trust in cell and gene therapies backed by real-world evidence.